2,000,000 Shares in Humacyte, Inc. $HUMA Purchased by Monashee Investment Management LLC

Key Points

• Monashee Investment Management LLC has acquired a new stake in Humacyte, buying 2,000,000 shares valued at approximately $3.41 million, now owning 1.29% of the company.
• Humacyte's recent earnings report reflected a loss per share of ($0.24), missing analyst estimates, while revenue was significantly lower than expected.
• Analysts have varying opinions on Humacyte, with a consensus rating of "Buy", although several have recently lowered their price targets for the stock.

Monashee Investment Management LLC purchased a new position in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,000,000 shares of the company's stock, valued at approximately $3,410,000. Monashee Investment Management LLC owned about 1.29% of Humacyte at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of HUMA. Geode Capital Management LLC grew its holdings in shares of Humacyte by 4.7% during the fourth quarter. Geode Capital Management LLC now owns 2,135,133 shares of the company's stock worth $10,785,000 after buying an additional 94,915 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Humacyte by 40.9% during the fourth quarter. Wells Fargo & Company MN now owns 50,454 shares of the company's stock worth $255,000 after buying an additional 14,649 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Humacyte by 19.5% during the fourth quarter. Legal & General Group Plc now owns 81,405 shares of the company's stock worth $411,000 after buying an additional 13,293 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Humacyte during the fourth quarter worth about $377,000. Finally, Rockefeller Capital Management L.P. purchased a new stake in shares of Humacyte during the fourth quarter worth about $251,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on HUMA shares. D. Boral Capital restated a "buy" rating and set a $25.00 price objective on shares of Humacyte in a report on Monday, August 11th. Wall Street Zen cut Humacyte from a "hold" rating to a "sell" rating in a report on Sunday, August 17th. Benchmark lowered their target price on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. HC Wainwright lowered their target price on shares of Humacyte from $4.00 to $3.00 and set a "buy" rating for the company in a report on Tuesday, August 12th. Finally, TD Cowen lowered their target price on shares of Humacyte from $5.00 to $3.50 and set a "buy" rating for the company in a report on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, Humacyte presently has an average rating of "Buy" and an average target price of $10.64.

Insider Transactions at Humacyte

In other Humacyte news, CEO Laura E. Niklason sold 1,100,000 shares of the business's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $1.63, for a total transaction of $1,793,000.00. Following the transaction, the chief executive officer owned 591,685 shares in the company, valued at $964,446.55. The trade was a 65.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Brady W. Dougan sold 1,100,000 shares of the business's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $1.63, for a total value of $1,793,000.00. Following the transaction, the director owned 591,685 shares in the company, valued at approximately $964,446.55. This represents a 65.02% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,482,090 shares of company stock worth $7,466,382. 5.10% of the stock is currently owned by insiders.

Humacyte Trading Down 4.3%

Humacyte stock traded down $0.07 during midday trading on Tuesday, reaching $1.44. The stock had a trading volume of 2,206,041 shares, compared to its average volume of 4,019,404. Humacyte, Inc. has a twelve month low of $1.15 and a twelve month high of $7.10. The stock has a market capitalization of $227.26 million, a PE ratio of -3.19 and a beta of 1.90. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.93 and a current ratio of 2.45. The stock's 50-day simple moving average is $2.21 and its 200 day simple moving average is $2.32.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). The business had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.94 million. Analysts expect that Humacyte, Inc. will post -1.27 EPS for the current year.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.